Blog

VANCOUVER, BC / ACCESS Newswire / October 16, 2025 / CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) (“CoTec” or the “Company”) is pleased to announce Québec-based BBA Inc. (“BBA”) has been engaged to complete the Lac Jeannine Iron Tailings Project (“Lac Jeannine” or the “Project”) bankable Feasibility Study (the “FS”) to engineer and design its Iron Tailings reclamation Project in Québec, Canada.

Julian Treger, CoTec CEO commented: “Lac Jeannine exemplifies CoTec’s strategy to deploy innovative, environmentally responsible technologies which transform legacy waste sites into valuable resources. The Project has the potential to deliver strong economic returns while simultaneously addressing historical environmental liabilities. Furthermore, the inclusion of adjacent tailings in the Project has the potential to almost double the life of mine with limited additional capex, unlocking substantial upside potential.

We are very excited to be working with BBA to complete the Feasibility Study and to position Lac Jeannine as a model for sustainable tailings redevelopment in Québec. During the Feasibility Study, discussions with strategic partners will be accelerated so the Project has the full support of all stakeholders, including the Government of Québec, First Nations and other interested parties. The results from the 2025 drilling and bulk sample, which are expected in Q1 2026, could also allow CoTec to increase its current resource estimate for Lac Jeannine.”

Lac Jeannine represents CoTec’s first stand-alone tailings reprocessing investment complementing the Company’s strategy to apply advanced technologies to unlock value from underutilized resource assets. The study will build on the positive results of the 2024 Preliminary Economic Assessment (“PEA”) announced on June 27, 2024ⁱ, which was based on only part of the total tailings and outlined a pre-tax NPV of US$93.6 million and an IRR of 38%, based on an initial capital investment of US$64.6 million. The Feasibility Study will include the application of the Salter Cyclone Multi-Gravity Separators (“MGS”) technology for the recovery of additional iron ore from the Project.

The Feasibility Study is expected to be completed through a staged approach by H2 2026. Lac Jeannine has the potential to produce high grade, critical mineral, iron ore concentrate at competitive cost structures which can deliver high purity iron concentrates for the green steel industry. The Lac Jeannine Project offers great potential for the resource industry to recover the economic benefit of large Fe tailing sites.

In September 2025, CoTec completed an infill and extension drilling campaign with the goal of upgrading to Indicated the existing Inferred Mineral Resource of 73 million tonnes at 6.7% total Fe, for 4.9 Mt of contained total Fe, and extending the Project to include a large part of the adjacent tailings not included in the PEA (“Adjacent Tailings”). The inclusion of the Adjacent Tailings has the potential to almost double the life of mine with limited additional capex, unlocking substantial upside potential. The Feasibility Study metallurgy testing will target the production of direct-reduction (“DR”) grade concentrate by the Project.

About Lac Jeannine

The Lac Jeannine Property comprises 31 mineral claims (exclusive exploration rights) covering 1,649 hectares in Québec’s Côte-Nord Region, approximately eight kilometres southeast of Gagnon and 290 kilometres north of Baie-Comeau. The Project encompasses the historic Lac Jeannine open-pit iron mine, which produced approximately 260 million long tons of ore averaging 33% Fe between 1961 and 1976.

The site includes a large Tailings Storage Facility (TSF) where concentrator tailings were deposited prior to mine closure and reclamation in 1984. CoTec’s focus is on reprocessing these tailings for residual iron recovery while rehabilitating the TSF.

The Independent Qualified Person as defined by NI 43-101 for the Lac Jeannine Mineral Resource, Mr. Christian Beaulieu, P.Geo., is a member of l’Ordre des géologues du Québec (#1072). The Qualified Person has reviewed and approved the scientific and technical content of this announcement relating to the Lac Jeannine Mineral Resource

About CoTec Holdings Corp.

CoTec Holdings Corp. (TSX-V:CTH)(OTCQB:CTHCF) is redefining the future of resource extraction and recycling. Focused on rare earth magnets and strategic materials, CoTec integrates breakthrough technologies with strategic assets to unlock secure, sustainable, and low-cost supply chains.

CoTec’s mission is clear: accelerate the energy transition while strengthening strategic critical mineral supply chains for the countries we operate in. By investing in and deploying disruptive technologies, the Company delivers capital-efficient, scalable solutions that transform marginal assets, tailings, waste streams, and recycled products into high-value critical minerals.

From its HyProMag USA magnet recycling joint venture in Texas, to iron tailings reprocessing in Québec, to next-generation copper and iron solutions backed by global majors, CoTec is building a diversified portfolio with long-term growth, rapid cash flow potential, and high barriers to entry. The result is a game-changing platform at the intersection of technology, sustainability, and strategic materials.

For more information, please visit www.cotec.ca.

For further information, please contact:

Braam Jonker – (604) 992-5600

Forward-Looking Information Cautionary Statement

Statements in this press release regarding the Company and its investments which are not historical facts are “forward-looking statements” which involve risks and uncertainties, including statements relating to the timing, scope, and completion of the Feasibility Study, the potential future value of the Project, the maiden resource estimate, the bulk sample extraction, the option exercise, and the Project, as well as management’s expectations with respect to the Lac Jeannine investment and other current and potential future investments, and the benefits to the Company which may be implied from such statements.

Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements due to known and unknown risks and uncertainties affecting the Company, including but not limited to: resource and reserve risks; environmental risks and costs; permitting and regulatory risks; labor costs and shortages; uncertain supply and price fluctuations in materials; increases in energy costs; labor disputes and work stoppages; equipment leasing and availability; heavy equipment demand and availability; contractor and subcontractor performance; worksite safety issues; project delays and cost overruns; extreme weather events; and social, transport, or geopolitical disruptions.

For further details regarding risks and uncertainties facing the Company, please refer to “Risk Factors” in the Company’s filing statement dated April 6, 2022, a copy of which may be found under the Company’s profile on SEDAR+ (www.sedarplus.ca). The Company assumes no obligation to update forward-looking statements in this press release except as required by law. Readers should not place undue reliance on the forward-looking statements and information contained in this news release and are encouraged to read the Company’s continuous disclosure documents available on SEDAR+ (www.sedarplus.ca).

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

ⁱ For further details, please refer to the technical report entitled “Mineral Resource Estimate, Preliminary Economic Assessment and NI 43-101 technical report for CoTec’s Lac Jeannine Fe Tailings Project, Québec, Canada” dated August 5, 2024 and having an effective date of March 19, 2024 prepared by Addison Mining Services Ltd., JPL GeoServices Inc., Soutex Inc., Amerston Consulting Ltd. and Axe Valley Mining Consultants Ltd. A copy of the technical report is available under CoTec’s profile on SEDAR+ (www.sedarplus.com) and the Company’s website

SOURCE: CoTec Holdings Corp.

View the original press release on ACCESS Newswire

• Enterprise platform, queried through natural language, to help pharma, biotech, and investors make better decisions.

• High-quality biological patient data, enriched and integrated for use by AI agents.

PARIS, FRANCE / ACCESS Newswire / October 16, 2025 / Owkin today announces the launch of K Pro, its co-pilot bringing advanced agentic AI to biomedical research and drug development. K Pro helps pharmaceutical companies and biotechs make smarter decisions across the discovery and development pipeline, increase clinical success rates, and deliver decision-grade, data-driven biological insights fast enough to change program trajectories.

Built on a decade of Owkin’s AI innovation and in close collaboration with leading academic and industry partners, K Pro is a scientist-first co-pilot, accessible to both researchers and executives. Through natural language interaction, users can ask complex biological questions and receive actionable, clinically relevant answers, unifying fragmented workflows into an insight-driven research experience.

At its core, K Pro integrates Owkin Zero, a fine-tuned biological LLM that performs biological reasoning with higher performance than other leading LLMs (read the full paper). Leveraging high-quality, multimodal biomedical datasets, K Pro gives researchers access to one of the deepest, curated, AI-ready multimodal oncology datasets available (including MOSAIC). Biopharma and academic clients can securely upload their proprietary datasets to leverage K Pro’s advanced AI reasoning and data analysis.

Thomas Clozel, MD, Owkin Co-founder and CEO, said: “K Pro brings us closer to intelligence that evolves with the complexity of biology. By combining advanced biological reasoning with an agentic co-pilot architecture, it represents a key step towards our mission of achieving Biological Artificial Super Intelligence (BASI), AI capable of modelling and engineering biology beyond what humans are capable of to deliver transformative therapies to patients faster.”

K Pro has already accelerated internal drug target identification by 70% (from 12+ months to 3 months); built an IND-ready asset positioning strategy in hours instead of months of traditional analysis; and written a specialist review in one day, which was later published in a peer-reviewed scientific journal.

K Pro builds upon Owkin’s proven approach to agentic AI biomedical discovery, validated through collaborations with leading pharmaceutical companies including AstraZeneca, Bristol Myers Squibb and Sanofi.

Ben Mellows, managing director at the biotech company Micregen, used Owkin K to formulate his investor pitch and shared his experience: “We wanted to get our product pitch across to investors. That process could take weeks to work through with all of our experts, but Owkin K really helped. It assimilated all the information we provided evidencing how our regenerative stem cell-derived platform and products could have a major impact on healthcare and delivered a clear story tailored to investors from different backgrounds. The literature set is huge. I would say the task would have been nearly impossible to achieve at the scale that Owkin K handled in just a few work sessions.”

Owkin’s AI has already delivered results for pharmaceutical clients, including: preventing Phase 2 clinical trial futility by identifying high-risk combination therapy populations; discovering new multimodal disease endotypes; reducing trial duration by three years (35%) by identifying the right patient segment to inform enrolment and identifying novel oncology targets.

About Owkin:
Owkin is an AI company on a mission to solve the complexity of biology. It is building the first Biology Super Intelligence (BASI) by combining powerful biological large language models, multimodal patient data, and agentic software. At the heart of this system is Owkin K, an AI co-pilot and its new LLM finetuned on biology called Owkin Zero, used by researchers, clinicians, and drug developers to better understand biology, validate scientific hypotheses, and deliver better diagnostics and therapies faster.

About the State of Agentic AI in Biopharma Report:
To ensure K Pro addresses the real-world challenges facing pharma, Owkin partnered with STAT Brand Studio to produce the State of the Nation report, surveying over 200 pharma executives (full report here). Nearly half of respondents identified overcoming data challenges as the area where agentic AI could deliver the greatest value. Early discovery, clinical trial optimisation, and translational research were also highlighted as top priorities, underscoring the immediate need for agentic AI solutions that translate complex biomedical data into actionable insights.

SOURCE: Owkin

Related Images

View the original press release on ACCESS Newswire

After decades shaping hits for artists including Carlos Santana, Tupac, Britney Spears, Kat Graham, Todrick Hall, Nicole Scherzinger, Beto Cuevas, La Ley, Luis Fonsi, David Bisbal (Spain), M. Pokora (France), Pixie Lott, and James Arthur (UK), Grammy-winning producer Jeeve steps into the spotlight with a kaleidoscopic visual journey through trauma, identity, and liberation.

LOS ANGELES, CA / ACCESS Newswire / October 15, 2025 / Jean-Yves “Jeeve” Ducornet, Founder of Crystal Ship Music, has been the creative force behind some of music’s most iconic voices for more than 35 years. A Grammy-winning producer, he has shaped records for Carlos Santana, Tupac, Britney Spears, Kat Graham, Todrick Hall, Nicole Scherzinger, Beto Cuevas, La Ley, Luis Fonsi, David Bisbal, Pixie Lott, James Arthur, and many others. His fingerprints are on platinum records and global hits – but with his new project, Spoken For – The Movie, Jeeve finally steps into the spotlight as the artist himself.

A Cinematic Album Experience

Two years in the making, Spoken For – The Movie is more than an album. It’s a 12-part visual odyssey – each track paired with its own AI-driven short film. Blending music, cinema, and generative art, the project traces a journey through inherited trauma, creative struggle, fleeting love, and ultimate rebirth.

Videos from Spoken For – The Movie have already earned honors at film festivals such as Chicago Filmmaker Awards, Video Musika, Mannheim Arts and Film Festival, San Diego Movie Awards, and many more.

“Our insecurities can be more cinematic than a blockbuster,” Jeeve says. “I wanted to create something that feels part therapy, part prophecy – and completely my own.”

Highlights from Spoken For-The Movie

“Why Do I” – A raw opening track confronting generational trauma and emotional paralysis, setting the tone for the journey ahead.

“That Thing That Makes You Win” – A biting satire of the music industry’s con artists, staged as an 1800s carnival where charisma outshines talent.

“Good As Perfect” – A wedding song stripped of fantasy, embracing flaws and friction as the true foundation of lasting love.

The title track, “Spoken For,” delivers the project’s most haunting metaphor: a child silenced by a controlling parent, visualized through an android whose cracking voice box reveals the vulnerable human underneath.

An Artist Reclaimed

Half French, half American, Jeeve has long lived in dualities – acclaimed music producer yet anonymous artist. With Spoken For – The Movie, he breaks that pattern. Writing, directing, producing, mixing, and editing virtually every element himself – using tools like Photoshop, Kling AI, Runway, Google Veo 3, Midjourney, and Topaz AI – Jeeve emerges as a true auteur.

“I’ve made music for others my whole career,” he reflects. “This is the first time I told myself what to do, and I finally listened.”

Release Date: January 9, 2026

Platforms: Streaming on all major platforms; visual films premiering on Apple TV, Amazon Prime Video, Google Play Movies, YouTube TV, and Fandango at Home.

Contact Information

Jean-Yves Ducornet
bigjeeve@gmail.com

SOURCE: Crystal Ship Music

View the original press release on ACCESS Newswire

SAN DIEGO, CA / ACCESS Newswire / October 15, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation, today announced that the Company as a result of insufficient shares present it has adjourned its 2025 Special Meeting of Stockholders (the “Special Meeting”) originally convened on October 15, 2025 to allow additional time for stockholders to vote on the proposals described in the Company’s proxy materials.

The meeting will reconvene on October 29, 2025, at 12:00 p.m., Eastern Time, and will continue to be held virtually via webcast at: https://bit.ly/4mmwxNY

The record date for the meeting, September 11, 2025, remains unchanged.

Stockholders who have already voted do not need to take any further action unless they wish to change their votes. Stockholders who have not yet voted are encouraged to do so before the new meeting date by following the instructions provided in the Company’s proxy materials.

The Company strongly encourages all stockholders, regardless of the number of shares they hold, to participate in the meeting and exercise their right to vote as soon as possible.

Additional information regarding the meeting and voting procedures is available in the Company’s proxy statement filed with the U.S. Securities and Exchange Commission (“SEC”) and accessible on the SEC’s website at:

https://www.sec.gov/Archives/edgar/data/1810560/000119312525211333/2025_special_meeting_def.htm

If you have questions about the proposals or if you need additional copies of this proxy statement/prospectus or the enclosed proxy card you should contact our proxy solicitor at:

Advantage Proxy
PO Box 10904
Yakima, WA 98909
Toll Free Phone: 1-877-870-8565
Collect: 1-206-870-8565
Email: ksmith@advantageproxy.com

About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as prevention for acute kidney injury and for the treatment of chronic kidney disease.

For more information, please visit www.RevBiosciences.com.

Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

Company Contacts
Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: mike@plrinvest.com

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com

SOURCE: Revelation Biosciences, Inc.

View the original press release on ACCESS Newswire